Zynex Medical Holdings, Inc. (OTC BB: ZYNX) has added a revolutionary new mode to their NeuroMove™ for spinal cord injury patients. Zynex's patent pending product, the NeuroMove™, has been used by numerous stroke victims since late 2003. The new mode is five times as sensitive as the stroke recovery mode enabling the identification of minute traces of brain to muscle activity.
As in stroke patients, spinal cord injury patients may have not used some extremities for years. Instead of simply stimulating the muscles, the NeuroMove™ teaches patients to realize their potential by giving them a "reward," or muscle stimulation, when an attempt is made by the brain to engage these muscles. This gives patients hope of regaining the ability to walk or use of their hands.
Thomas Sandgaard, CEO of Zynex Medical Holdings, Inc. commented, "We are extremely excited to introduce this ground-breaking therapy for spinal cord injury patients. Our unique approach to therapy is helping patients gain mobility in cases that other therapy has proven ineffective."
ABOUT ZYNEX MEDICAL, INC.:
Since 1996, Zynex has been a leading provider of relief for patients with functional disability through the creation, distribution and marketing of the highest quality electrotherapy products available today. Zynex continually strives to uphold its mission to improve the quality of life of patients suffering from debilitating pain or illness by providing the highest technology and service standards in the electrotherapy industry. Utilizing various methods of non-invasive muscle stimulation and state-of-the-art electromyography technology, Interferential Current (IFC) and Transcutaneous Electrical Nerve Stimulation (TENS), Zynex offers patients a new lease on life through increased mobility and independence.
"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.